344 related articles for article (PubMed ID: 21784355)
1. Costs of care in a mild-to-moderate Alzheimer clinical trial sample: key resources and their determinants.
Gustavsson A; Cattelin F; Jönsson L
Alzheimers Dement; 2011 Jul; 7(4):466-73. PubMed ID: 21784355
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.
Sparks DL; Sabbagh MN; Connor DJ; Lopez J; Launer LJ; Browne P; Wasser D; Johnson-Traver S; Lochhead J; Ziolwolski C
Arch Neurol; 2005 May; 62(5):753-7. PubMed ID: 15883262
[TBL] [Abstract][Full Text] [Related]
3. Cost and care of patients with Alzheimer's disease: clinical predictors in German health care settings.
Reese JP; Hessmann P; Seeberg G; Henkel D; Hirzmann P; Rieke J; Baum E; Dannhoff F; Müller MJ; Jessen F; Geldsetzer MB; Dodel R
J Alzheimers Dis; 2011; 27(4):723-36. PubMed ID: 21876256
[TBL] [Abstract][Full Text] [Related]
4. Determinants of costs of care for patients with Alzheimer's disease.
Jönsson L; Eriksdotter Jönhagen M; Kilander L; Soininen H; Hallikainen M; Waldemar G; Nygaard H; Andreasen N; Winblad B; Wimo A
Int J Geriatr Psychiatry; 2006 May; 21(5):449-59. PubMed ID: 16676288
[TBL] [Abstract][Full Text] [Related]
5. Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials.
Coley N; Andrieu S; Jaros M; Weiner M; Cedarbaum J; Vellas B
Alzheimers Dement; 2011 Nov; 7(6):602-610.e2. PubMed ID: 21745761
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.
Sevigny JJ; Ryan JM; van Dyck CH; Peng Y; Lines CR; Nessly ML;
Neurology; 2008 Nov; 71(21):1702-8. PubMed ID: 19015485
[TBL] [Abstract][Full Text] [Related]
7. Patients with Lewy body dementia use more resources than those with Alzheimer's disease.
Boström F; Jönsson L; Minthon L; Londos E
Int J Geriatr Psychiatry; 2007 Aug; 22(8):713-9. PubMed ID: 17195278
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
Jönsson L
Am J Geriatr Pharmacother; 2005 Jun; 3(2):77-86. PubMed ID: 16129384
[TBL] [Abstract][Full Text] [Related]
9. A neuropsychological test battery for use in Alzheimer disease clinical trials.
Harrison J; Minassian SL; Jenkins L; Black RS; Koller M; Grundman M
Arch Neurol; 2007 Sep; 64(9):1323-9. PubMed ID: 17846273
[TBL] [Abstract][Full Text] [Related]
10. Long-term progression of Alzheimer's disease in patients under antidementia drugs.
Gillette-Guyonnet S; Andrieu S; Nourhashemi F; Gardette V; Coley N; Cantet C; Gauthier S; Ousset PJ; Vellas B;
Alzheimers Dement; 2011 Nov; 7(6):579-92. PubMed ID: 22055975
[TBL] [Abstract][Full Text] [Related]
11. Time use and costs of institutionalised elderly persons with or without dementia: results from the Nordanstig cohort in the Kungsholmen Project--a population based study in Sweden.
Nordberg G; Wimo A; Jönsson L; Kåreholt I; Sjölund BM; Lagergren M; von Strauss E
Int J Geriatr Psychiatry; 2007 Jul; 22(7):639-48. PubMed ID: 17225239
[TBL] [Abstract][Full Text] [Related]
12. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis.
Cummings JL; Ferris SH; Farlow MR; Olin JT; Meng X
Dement Geriatr Cogn Disord; 2010; 29(5):406-12. PubMed ID: 20502014
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
14. A community-based exercise programme to improve functional ability in people with Alzheimer's disease: a randomized controlled trial.
Vreugdenhil A; Cannell J; Davies A; Razay G
Scand J Caring Sci; 2012 Mar; 26(1):12-9. PubMed ID: 21564154
[TBL] [Abstract][Full Text] [Related]
15. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
16. Relation between severity of Alzheimer's disease and costs of caring.
Hux MJ; O'Brien BJ; Iskedjian M; Goeree R; Gagnon M; Gauthier S
CMAJ; 1998 Sep; 159(5):457-65. PubMed ID: 9757169
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
Wilkinson D; Andersen HF
Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
[TBL] [Abstract][Full Text] [Related]
19. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain.
Antonanzas F; Rive B; Badenas JM; Gomez-Lus S; Guilhaume C
Eur J Health Econ; 2006 Jun; 7(2):137-44. PubMed ID: 16670912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
